Compare ADPT & GEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADPT | GEL |
|---|---|---|
| Founded | 2009 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil Refining/Marketing |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2019 | 1996 |
| Metric | ADPT | GEL |
|---|---|---|
| Price | $17.07 | $15.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | $17.78 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 1.7M | 219.3K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 4.19% |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $276,976,000.00 | ★ $2,912,770,000.00 |
| Revenue This Year | $3.98 | $12.12 |
| Revenue Next Year | $22.72 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 54.77 | 43.60 |
| 52 Week Low | $9.96 | $14.55 |
| 52 Week High | $20.76 | $18.64 |
| Indicator | ADPT | GEL |
|---|---|---|
| Relative Strength Index (RSI) | 66.43 | 46.97 |
| Support Level | $14.87 | $14.92 |
| Resistance Level | $17.52 | $16.44 |
| Average True Range (ATR) | 0.93 | 0.47 |
| MACD | 0.33 | 0.05 |
| Stochastic Oscillator | 81.33 | 49.69 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Genesis Energy LP focuses on the midstream segment of the crude oil and natural gas industry. It offers various services to crude oil and natural gas producers, and industrial and commercial enterprises. The company's reportable segments are: Offshore pipeline transportation, Marine transportation, and Onshore transportation and services. Maximum revenue is generated from the Offshore pipeline transportation segment, which includes the transportation and processing of crude oil and natural gas in the Gulf of America. The Marine transportation segment provides waterborne transportation of petroleum products and crude oil throughout North America; and the Onshore transportation and services segment deals with crude oil logistics, sour gas processing, and sells sulfur byproducts.